Lisata Therapeutics Inc. Reports Recent Financial Performance

Lisata Therapeutics, Inc., a biopharmaceutical company specializing in cardiovascular and autoimmune disease treatments, has recently reported its financial performance. The company, which operates globally within the health care sector’s biotechnology industry, is traded on the Nasdaq under the ticker symbol LSTA.

As of June 24, 2025, Lisata Therapeutics closed at a price of $2.52 per share. This figure is part of a broader financial context where the company’s stock has experienced significant fluctuations over the past year. The 52-week high was recorded at $4.20 on January 5, 2025, while the 52-week low was $1.87 on April 6, 2025.

The company’s market capitalization stands at approximately $20,890,000 USD, reflecting its current valuation in the market. However, the price-to-earnings (P/E) ratio is currently at -1.08, indicating that the company is not yet profitable or is experiencing losses.

Lisata Therapeutics continues to focus on its core mission of developing innovative products for cardiovascular and autoimmune diseases. The company’s efforts are aimed at addressing unmet medical needs and improving patient outcomes worldwide. For more detailed information about their product offerings and research initiatives, interested parties can visit their website at www.caladrius.com .

As the biotechnology sector continues to evolve, Lisata Therapeutics remains committed to advancing its research and development efforts to bring new therapies to market. The company’s strategic focus on cardiovascular and autoimmune diseases positions it to potentially capitalize on growing demand in these therapeutic areas.